Literature DB >> 18205883

Reproductive counselling, treatment and course of pregnancy in 73 German MS patients.

K Hellwig1, N Brune, A Haghikia, T Müller, S Schimrigk, V Schwödiauer, R Gold.   

Abstract

Multiple sclerosis (MS) often affects women during the reproductive years of their life. During this period, issues such as choice of immunomodulatory treatment, seeking advice from specialists, relapse-induced steroid application before, during or after pregnancy in combination with breastfeeding gain importance. The objective was to investigate these issues retrospectively using a questionnaire among 73 MS patients with a total of 88 pregnancies. Eighty per cent of the participants consulted their neurologists before and 60% during pregnancy. The annual relapse rate decreased during pregnancy and significantly increased during the first 3 months after delivery. Immunomodulatory treatment was stopped due to desired pregnancy for a mean of 4 years. Fourteen of the MS patients received intravenous immunoglobulin treatment post-natal. Ninety per cent of the study subjects started breastfeeding. However, nearly 30% ablactated, as they received steroids due to a relapse. Weight and height of the full-term children of singleton pregnancies from MS patients were significantly lower compared with the ones of age-matched healthy controls. Our results confirm the known reduced relapse rate during pregnancy, which is followed by an increased relapse rate after delivery. They shed light on the epidemiology of childbirth in patients with MS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18205883     DOI: 10.1111/j.1600-0404.2007.00978.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  17 in total

1.  Immunomodulation and postpartum relapses in patients with multiple sclerosis.

Authors:  Kerstin Hellwig; Christian Beste; Sebastian Schimrigk; Andrew Chan
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

2.  Interferon beta, birth weight and pregnancy in multiple sclerosis.

Authors:  Kerstin Hellwig; Heike Agne; Ralf Gold
Journal:  J Neurol       Date:  2009-02-25       Impact factor: 4.849

Review 3.  Pregnancy and multiple sclerosis.

Authors:  Laura Airas; Risto Kaaja
Journal:  Obstet Med       Date:  2012-05-29

Review 4.  Contraception for women with multiple sclerosis: Guidance for healthcare providers.

Authors:  Maria K Houtchens; Lauren B Zapata; Kathryn M Curtis; Maura K Whiteman
Journal:  Mult Scler       Date:  2017-03-24       Impact factor: 6.312

5.  Multiple sclerosis and pregnancy: experience from a nationwide database in Germany.

Authors:  Kerstin Hellwig; Aiden Haghikia; Milena Rockhoff; Ralf Gold
Journal:  Ther Adv Neurol Disord       Date:  2012-09       Impact factor: 6.570

Review 6.  Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.

Authors:  Ellen Lu; Bing Wei Wang; Colleen Guimond; Anne Synnes; Dessa Sadovnick; Helen Tremlett
Journal:  Neurology       Date:  2012-08-29       Impact factor: 9.910

Review 7.  Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner.

Authors:  Celia Oreja-Guevara; Heinz Wiendl; Bernd C Kieseier; Laura Airas
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

8.  Parenthood and immunomodulation in patients with multiple sclerosis.

Authors:  Kerstin Hellwig; Aiden Haghikia; Ralf Gold
Journal:  J Neurol       Date:  2009-11-21       Impact factor: 4.849

9.  Disease-Modifying Drug Possibly Linked to Placental Insufficiency: Severe placental complications in a pregnant woman with multiple sclerosis.

Authors:  Sultan M Salahudheen; Muzibunnisa A Begam
Journal:  Sultan Qaboos Univ Med J       Date:  2016-08-19

10.  Assessment of ovarian reserve and Doppler characteristics in patients with multiple sclerosis using immunomodulating drugs.

Authors:  Aylin Pelin Cil; Alev Leventoğlu; Murat Sönmezer; Rabia Soylukoç; Kutluk Oktay
Journal:  J Turk Ger Gynecol Assoc       Date:  2009-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.